Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Alashek, Wiam A ^a   McIntyre, Christopher W ^a,b   Taal, Maarten W ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b DERBY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Haemodialysis; Hepatitis B; Hepatitis C; Incidence; Libya; Nosocomial infection; Prevalence

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ADULT; AGE DISTRIBUTION; ANEMIA; ANTIGEN DETECTION; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; DISEASE TRANSMISSION; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HEPATITIS B; HEPATITIS C; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION RISK; KIDNEY TRANSPLANTATION; LIBYAN ARAB JAMAHIRIYA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEROCONVERSION; SEX DIFFERENCE; TREATMENT DURATION;

ADULT; CROSS INFECTION; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INCIDENCE; LIBYA; MALE; MIDDLE AGED; PREVALENCE; RENAL DIALYSIS; RISK FACTORS;

EID: 84867615483     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-265     Document Type: Article

References (49)

1. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002, 36(1):3-10.
2. Fabrizi F, Lunghi G, Martin P. Hepatitis B virus infection in hemodialysis: recent discoveries. J Nephrol 2002, 15(5):463-468.
3. Taal MW, van Zyl-Smit R. Hepatitis C virus infection in chronic haemodialysis patients-relationship to blood transfusions and dialyser re-use. S Afr Med J 2000, 90(6):621-625.
4. Knudsen F, Wantzin P, Rasmussen K, Ladefoged SD, Lokkegaard N, Rasmussen LS, Lassen A, Krogsgaard K. Hepatitis C in dialysis patients: relationship to blood transfusions, dialysis and liver disease. Kidney Int 1993, 43(6):1353-1356. 10.1038/ki.1993.190, 7686238.
5. Allander T, Medin C, Jacobson SH, Grillner L, Persson MA. Hepatitis C transmission in a hemodialysis unit: molecular evidence for spread of virus among patients not sharing equipment. J Med Virol 1994, 43(4):415-419. 10.1002/jmv.1890430417, 7545963.
6. Le Pogam S, Le Chapois D, Christen R, Dubois F, Barin F, Goudeau A. Hepatitis C in a hemodialysis unit: molecular evidence for nosocomial transmission. J Clin Microbiol 1998, 36(10):3040-3043. 105107, 9738063.
7. Ozer A, Yakupogullari Y, Beytur A, Beytur L, Koroglu M, Salman F, Aydogan F. Risk factors of hepatitis B virus infection in turkey: a population-based, case-control study: risk factors for HBV infection. Hepat Mon 2011, 11(4):263-268. 3206693, 22087152.
8. Fabrizi F, Marzano A, Messa P, Martin P, Lampertico P. Hepatitis B virus infection in the dialysis population: current perspectives. Int J Artif Organs 2008, 31(5):386-394.
9. Taal MW, van Zyl-Smit R. Cost-effectiveness of hepatitis B vaccination in haemodialysis patients. S Afr Med J 2001, 91(4):340-344.
10. Mohamed WZ. Prevention of hepatitis C virus in hemodialysis patients: five years experience from a single center. Saudi J Kidney Dis Transpl 2010, 21(3):548-554.
11. Patel PR, Thompson ND, Kallen AJ, Arduino MJ. Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients. Am J Kidney Dis 2010, 56(2):371-378. 10.1053/j.ajkd.2010.01.025, 20570422.
12. Saune K, Kamar N, Miedouge M, Weclawiak H, Dubois M, Izopet J, Rostaing L. Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant 2010, 26(7):2309-2316.
13. Alashek WA, McIntyre CW, Taal MW. Provision and quality of dialysis services in Libya. Hemodial Int 2011, 15(4):444-452. 10.1111/j.1542-4758.2011.00588.x, 22111812.
14. Elzouki A, Esmeo M, Samod M, Abonaja A, Alagi B, Daw M. Prevalence of hepatitis B, C and HIV infection in Libya: a population-based nationwide seropepidemiological study. Liver Int 2006, 26:20.
15. Elzouki AN. Hepatitis B infection in Libya:The magnitude of the problem. The Libyan Journal of Infectious Diseases 2008, 2(1):20-25.
16. Daw MA, Elkaber MA, Drah AM, Werfalli MM, Mihat AA, Siala IM. Prevalence of hepatitis C virus antibodies among different populations of relative and attributable risk. Saudi Med J 2002, 23(11):1356-1360.
17. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000, 355(9207):887-891. 10.1016/S0140-6736(99)06527-7, 10752705.
18. Lavanchy D. The global burden of hepatitis C. Liver Int 2009, 29(Suppl 1):74-81.
19. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010, 14(1):1-21. vii, 10.1016/j.cld.2009.11.009, 20123436.
20. WHO Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the viral hepatitis prevention board, antwerp, belgium. J Viral Hepat 1999, 6(1):35-47. WHO.
21. Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Folsch UR, Schmidt WE. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut 2002, 51(3):429-433. 10.1136/gut.51.3.429, 1773370, 12171969.
22. Boulaajaj K, Elomari Y, Elmaliki B, Madkouri B, Zaid D, Benchemsi N. Prevalence of hepatitis C, hepatitis B and HIV infection among haemodialysis patients in Ibn-rochd university hospital, casablanca. Nephrol Ther 2005, 1(5):274-284. 10.1016/j.nephro.2005.06.012, 16895696.
23. Souqiyyeh MZ, Al-Attar MB, Zakaria H, Shaheen FA. Dialysis centers in the kingdom of saudi arabia. Saudi J Kidney Dis Transpl 2001, 12(3):293-304.
24. Jemni S, Ikbel K, Kortas M, Mahjoub J, Ghachem L, Bidet JM, Boukef K. Seropositivity to hepatitis C virus in Tunisian haemodialysis patients. Nouv Rev Fr Hematol 1994, 36(5):349-351.
25. Yakaryilmaz F, Gurbuz OA, Guliter S, Mert A, Songur Y, Karakan T, Keles H. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail 2006, 28(8):729-735. 10.1080/08860220600925602, 17162434.
26. Batieha A, Abdallah S, Maghaireh M, Awad Z, Al-Akash N, Batieneh A, Ajlouni KA. Epidemiology and cost of haemodialysis in Jordan. East Mediterr Health J 2007, 13(3):654-663.
27. Goodkin DA, Young EW, Kurokawa K, Prutz KG, Levin NW. Mortality among hemodialysis patients in europe, japan, and the united states: case-mix effects. Am J Kidney Dis 2004, 44(5 Suppl 2):16-21.
28. Burdick RA, Bragg-Gresham JL, Woods JD, Hedderwick SA, Kurokawa K, Combe C, Saito A, LaBrecque J, Port FK, Young EW. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2003, 63(6):2222-2229. 10.1046/j.1523-1755.2003.00017.x, 12753311.
29. Ferreira RC, Teles SA, Dias MA, Tavares VR, Silva SA, Gomes SA, Yoshida CF, Martins RM. Hepatitis B virus infection profile in hemodialysis patients in Central Brazil: prevalence, risk factors, and genotypes. Mem Inst Oswaldo Cruz 2006, 101(6):689-692. 10.1590/S0074-02762006000600019, 17072485.
30. Chandra M, Khaja MN, Hussain MM, Poduri CD, Farees N, Habeeb MA, Krishnan S, Ramareddy GV, Habibullah CM. Prevalence of hepatitis B and hepatitis C viral infections in Indian patients with chronic renal failure. Intervirology 2004, 47(6):374-376. 10.1159/000080883, 15564751.
31. Qadi AA, Tamim H, Ameen G, Bu-Ali A, Al-Arrayed S, Fawaz NA, Almawi WY. Hepatitis B and hepatitis C virus prevalence among dialysis patients in Bahrain and Saudi Arabia: a survey by serologic and molecular methods. Am J Infect Control 2004, 32(8):493-495. 10.1016/j.ajic.2003.12.009, 15573057.
32. Telaku S, Fejza H, Elezi Y, Bicaj T. Hepatitis B and C in dialysis units in Kosova. Virol J 2009, 6:72. 10.1186/1743-422X-6-72, 2694791, 19497116.
33. SCOT Saudi centre for organ transplantation- annual report 2009 2009, (https://www.scot.org.sa/en/M) accessed July 2010, SCOT.
34. Al Hijazat M, Ajlouni YM. Hepatitis B infection among patients receiving chronic hemodialysis at the royal medical services in jordan. Saudi J Kidney Dis Transpl 2008, 19(2):260-267.
35. Alashek WA, McIntyre CW, Taal MW. Determinants of survival in patients receiving dialysis in Libya. Hemodial Int 2012, [Epub ahead of print].
36. Saxena AK, Panhotra BR. The vulnerability of middle-aged and elderly patients to hepatitis C virus infection in a high-prevalence hospital-based hemodialysis setting. J Am Geriatr Soc 2004, 52(2):242-246. 10.1111/j.1532-5415.2004.52062.x, 14728634.
37. Mostaghni AA, Soltanian A, Mokhtari E, Japoni S, Mehrabani D. Seroprevalence of hepatitis B virus among hemodialysis patients in Bushehr province, southern Iran: HBV seroprevalence in hemodialysis patients. Hepat Mon 2011, 11(3):200-202. 3206679, 22087144.
38. Hardy NM, Sandroni S, Danielson S, Wilson WJ. Antibody to hepatitis C virus increases with time on hemodialysis. Clin Nephrol 1992, 38(1):44-48.
39. Jasuja S, Gupta AK, Choudhry R, Kher V, Aggarwal DK, Mishra A, Agarwal M, Sarin A, Mishra MK, Raina V. Prevalence and associations of hepatitis C viremia in hemodialysis patients at a tertiary care hospital. Indian J Nephrol 2009, 19(2):62-67. 10.4103/0971-4065.53324, 2847810, 20368926.
40. Vladutiu DS, Cosa A, Neamtu A, State D, Braila M, Gherman M, Patiu IM, Dulau-Florea I. Infections with hepatitis B and C viruses in patients on maintenance dialysis in Romania and in former communist countries: yellow spots on a blank map?. J Viral Hepat 2000, 7(4):313-319. 10.1046/j.1365-2893.2000.00222.x, 10886543.
41. Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, Rayner HC, Greenwood RN, Akiba T, Young EW. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004, 65(6):2335-2342. 10.1111/j.1523-1755.2004.00649.x, 15149347.
42. Hitzler WE, Runkel S. Routine HCV PCR screening of blood donations to identify early HCV infection in blood donors lacking antibodies to HCV. Transfusion 2001, 41(3):333-337. 10.1046/j.1537-2995.2001.41030333.x, 11274586.
43. Doghman NA MYA, Najem FI, SA E-S. Blood donor screening for hepatitis B and C in Benghazi: additional tests are needed. Libyan J Infect Dis 2007, 1(1):100-102.
44. Pereira BJ. Hepatitis C infection and post-transplantation liver disease. Nephrol Dial Transplant 1995, 10(Suppl 1):58-67.
45. Dusheiko G, Song E, Bowyer S, Whitcutt M, Maier G, Meyers A, Kew MC. Natural history of hepatitis B virus infection in renal transplant recipients-a fifteen-year follow-up. Hepatology 1983, 3(3):330-336.
46. Izopet J, Sandres-Saune K, Kamar N, Salama G, Dubois M, Pasquier C, Rostaing L. Incidence of HCV infection in French hemodialysis units: a prospective study. J Med Virol 2005, 77(1):70-76. 10.1002/jmv.20415, 16032714.
47. Alavian SM, Bagheri-Lankarani K, Mahdavi-Mazdeh M, Nourozi S. Hepatitis B and C in dialysis units in Iran: changing the epidemiology. Hemodial Int 2008, 12(3):378-382. 10.1111/j.1542-4758.2008.00284.x, 18638096.
48. Karkar A, Abdelrahman M, Ghacha R, Malik TQ. Prevention of viral transmission in HD units: the value of isolation. Saudi J Kidney Dis Transpl 2006, 17(2):183-188.
49. Abu El Makarem MA, Abdel Hamid M, Abdel Aleem A, Ali A, Shatat M, Sayed D, Deaf A, Hamdy L, Tony EA. Prevalence of occult hepatitis B virus infection in hemodialysis patients from egypt with or without hepatitis C virus infection. Hepat Mon 2012, 12(4):253-258. 3360934, 22690232.